BOB体育

In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive鈥�

Investigator

Ashley Ghiaseddin

Status

Accepting Candidates

Ages

18 Years - 90 Years

Sexes

All

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune庐 (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune庐 together with鈥�

Investigator

Ashley Ghiaseddin

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma

Investigator

Ashley Ghiaseddin

Status

Accepting Candidates

Ages

18 Years - 80 Years

Sexes

All